Cardium Reports on First Quarter 2008 Highlights and Financi... (rt attack and require angioplasty and st...)

Cardium Reports on First Quarter 2008 Highlights and Financial Results

Date:5/9/2008

rt attack and require angioplasty and stent procedures.

Patients randomized to the cooling arm (hypothermia) will be infused

with one liter of iced saline in addition to endovascular cooling and

patients assigned to the normothermia arm will receive routine standard

of care without induced hypothermia. Additional information about the

-- Ongoing patient recruitment for the Company's Phase 3 Generx AWARE and

Phase 2b Excellarate MATRIX clinical trials. The AWARE clinical trial

is evaluating Generx as a potential treatment for myocardial ischemia

(insufficient blood flow within the heart muscle) which gives rise to

angina and is expected to enroll approximately 300 women at an

estimated 50 U.S. medical centers. Additional information about the

The MATRIX clinical trial is evaluating the safety and efficacy of

Excellarate for the potential treatment of non-healing diabetic foot

ulcers and is expected to enroll approximately 210 patients at up to

40 U.S. sites. Additional information about the MATRIX study can be

-- Addition of Richard A. Schatz, M.D. to Cardium's Scientific Advisory

Board. Dr. Schatz is a pioneer of coronary stent technology and is

Research Director of Cardiovascular Interventions at the Heart, Lung,

and Vascular Center at Scripps Clinic in La Jolla, California.

-- Broadcast of the Science Channel's "Cool Stuff: How it Works" series

featuring the use of InnerCool's end
'/>"/>

Post Your Comments:

Cardium Reports on First Quarter 2008 Highlights and Financi...(rt attack and require angioplasty and st...)